A detailed history of First Trust Advisors LP transactions in Legend Biotech Corp stock. As of the latest transaction made, First Trust Advisors LP holds 11,721 shares of LEGN stock, worth $384,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,721
Holding current value
$384,214
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$43.55 - $59.88 $510,449 - $701,853
11,721 New
11,721 $571,000
Q1 2024

May 13, 2024

BUY
$55.06 - $69.99 $1.15 Million - $1.46 Million
20,845 Added 87.55%
44,653 $2.5 Million
Q4 2023

Feb 13, 2024

SELL
$57.25 - $69.74 $1.74 Million - $2.12 Million
-30,351 Reduced 56.04%
23,808 $1.43 Million
Q3 2023

Nov 13, 2023

BUY
$63.16 - $76.5 $345,485 - $418,455
5,470 Added 11.23%
54,159 $3.64 Million
Q2 2023

Aug 14, 2023

SELL
$46.28 - $75.01 $2.44 Million - $3.96 Million
-52,771 Reduced 52.01%
48,689 $3.36 Million
Q1 2023

May 15, 2023

SELL
$43.42 - $57.37 $9.78 Million - $12.9 Million
-225,191 Reduced 68.94%
101,460 $4.89 Million
Q4 2022

Feb 09, 2023

BUY
$38.8 - $55.46 $2.96 Million - $4.23 Million
76,315 Added 30.49%
326,651 $16.3 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $6.6 Million - $9.88 Million
172,980 Added 223.62%
250,336 $10.2 Million
Q2 2022

Aug 12, 2022

SELL
$33.54 - $55.0 $49,840 - $81,730
-1,486 Reduced 1.88%
77,356 $4.26 Million
Q1 2022

May 13, 2022

SELL
$31.02 - $48.18 $817,408 - $1.27 Million
-26,351 Reduced 25.05%
78,842 $2.87 Million
Q4 2021

Feb 08, 2022

BUY
$41.14 - $56.98 $4.33 Million - $5.99 Million
105,193 New
105,193 $4.9 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.